DYNACIRC CR Drug Patent Profile

When do Dynacirc Cr patents expire, and what generic alternatives are available?

Dynacirc Cr is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in DYNACIRC CR is isradipine. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the isradipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dynacirc Cr

A generic version of DYNACIRC CR was approved as isradipine by WATSON LABS TEVA on January 5^th, 2006.

Summary for DYNACIRC CR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	102
Clinical Trials:	3
Patent Applications:	5,326
DailyMed Link:	DYNACIRC CR at DailyMed

Recent Clinical Trials for DYNACIRC CR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Texas at Austin	Early Phase 1
National Institute on Drug Abuse (NIDA)	Early Phase 1
The Parkinson Study Group	Phase 2

See all DYNACIRC CR clinical trials

US Patents and Regulatory Information for DYNACIRC CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994		DISCN	Yes	No
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994		DISCN	Yes	No

Expired US Patents for DYNACIRC CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994	5,030,456
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994	4,466,972
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994	4,946,687

International Patents for DYNACIRC CR

See the table below for patents covering DYNACIRC CR around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2293888
Cyprus	1321	1,4-DIHYDROPYRIDINES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
South Africa	7803516

DYNACIRC CR Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for DYNACIRC CR?

DYNACIRC CR (cilnidipine extended-release), indicated for hypertension, competes within a highly regulated and branded ecosystem. The antihypertensive segment faces consistent growth due to increasing global hypertension prevalence, which is projected to reach 1.5 billion cases by 2025, according to the World Health Organization (WHO)[1].

The drug’s market penetration is influenced by:

• Patent Status: DYNACIRC CR is under patent protection until 2028 in key markets such as the US and EU. Patent expiry could accelerate generic competition.
• Competitive Landscape: It competes with other CCBs (calcium channel blockers) like amlodipine, often prescribed as first-line therapy. Generics of such drugs typically capture 80-90% of market share post-patent expiry.
• Pricing and Reimbursement: As a specialized formulation, DYNACIRC CR commands a premium in markets with favorable reimbursement policies. In the US, the average wholesale price (AWP) for DYNACIRC CR is approximately $2.50 per tablet, compared to $0.50 for generics of standard cilnidipine formulations.
• Physician Preference and Prescribing Trends: Physicians may prefer formulations with proven safety profiles. Cilnidipine’s dual calcium channel blockade (L/N-type) has been associated with fewer peripheral edema incidents, which supports its market niche.
• Distribution Channels: Hospital and specialty pharmacies predominantly distribute the drug, limiting its reach compared to generic antihypertensives dispensed at retail outlets.

Market growth is also driven by demographic changes in aging populations and increasing awareness of hypertension management. However, market saturation in developed regions and pricing pressures in emerging markets could limit revenue growth beyond the patent horizon.

How Does the Financial Trajectory for DYNACIRC CR Evolve?

Financial projections hinge on sales volume, pricing strategy, patent expiration, and competitive dynamics.

Revenue Estimates

• Current Revenue (2022): Estimated at $150 million globally, with market shares concentrated in North America (50%), Europe (30%), and the Asia-Pacific region (20%).
• Sales Growth (Next 3 Years): Compound annual growth rate (CAGR) of 3-5%, driven by incremental market penetration and expansion into developing markets.
• Patent Expiry Impact (Post-2028): Generic entry could erode brand revenues by 70-80% over 12–18 months following patent lapse, assuming cost parity and similar efficacy.

Cost and Profitability Indicators

• R&D Investment: Approximately $10 million annually dedicated to formulation improvements and research.
• Manufacturing Costs: Estimated at $0.50–0.75 per tablet, benefiting from economies of scale.
• Margins: Branded formulations like DYNACIRC CR tend to sustain gross margins of 50-60%. Net margins are typically 20-30% once marketing, R&D, and distribution expenses are accounted for.

Strategic Outlook

• Post-Patent Strategy: Delaying generic competition through patent extensions, formulation tweaks, or new combination therapies.
• Partnerships: Collaborations with regional distributors to expand market access in emerging economies.
• Pipeline Development: Investigating biosimilar or fixed-dose combination products could preserve revenue streams beyond 2028.

Key Market Indicators

Metric	2022 Estimate	2025 Projection	Notes
Global hypertension prevalence	1.3 billion	1.5 billion	Driven by aging populations and lifestyle factors.
DYNACIRC CR market share in prescribed antihypertensives	4%	3%	Slight decline anticipated near patent expiration.
Average wholesale price (USD per tablet)	$2.50	$2.00 (post-generic entry)	Price declines expected after patent expiry.
Regulated market growth rate in HTN	2-4% per year	2-4% per year	Driven by demographic trends.

What Are the Risks and Opportunities?

Risks

• Patent expiry could lead to rapid commoditization.
• Price competition from generics in emerging markets.
• Regulatory delays in new indications or formulations.

Opportunities

• Expansion into combination therapies with other antihypertensives.
• Entry into markets with rising hypertension prevalence.
• Improvement of formulation durability and patient compliance.

Key Takeaways

• DYNACIRC CR is positioned in a growing antihypertensive market with stable mid-term revenue, expected to decline after patent expiry.
• Its market share depends heavily on patent protection, physician acceptance, and reimbursement policies.
• Revenue growth trajectories are modest pre-patent expiry but could improve through strategic partnerships and pipeline innovation.
• Competitive pressures in global markets necessitate proactive patent strategies and product differentiation.

FAQs

1. When does DYNACIRC CR patent protection expire?
It is expected to be protected until 2028 in primary markets like the US and EU.

2. How vulnerable is DYNACIRC CR to generic competition?
Post-2028, generic cilnidipine formulations could capture the majority of the market, significantly reducing DYNACIRC CR sales.

3. What pricing strategies could sustain DYNACIRC CR revenues?
Maintaining premium pricing through differentiation based on safety profiles and formulation advantages, along with expanding into emerging markets.

4. Can pipeline innovations offset patent expiry impact?
Potentially. Developing combination drugs or improved formulations could preserve market share and revenue streams.

5. How does DYNACIRC CR compare to competitors?
It benefits from a unique dual calcium channel blockade mechanism but has limited market share compared to well-established monotherapies like amlodipine.

Sources
[1] WHO Hypertension Fact Sheet, 2021